摘要
免疫治疗可通过提高患者自身免疫力以达到抗肿瘤目的,其中嵌合型抗原受体修饰T细胞(chimeric antigen receptor modified T cells,CAR-T)在血液系统肿瘤中已显现出良好疗效。实体肿瘤微环境(tumor microenvironment,TME)中免疫抑制细胞及分子等可限制CAR-T细胞在肿瘤部位浸润及其在浸润部位产生细胞毒作用。因此CAR-T细胞治疗在血液系统肿瘤中的显著疗效未在实体肿瘤中呈现。本文就如何突破TME限制,提高CAR-T细胞归巢能力及细胞毒作用,从而提高其在实体瘤中的疗效做一综述。
Immunotherapy can improve the patient's own immunity to achieve the purposes of anti-tumor,wherein chimeric antigen receptor modified T cells(CAR-T)have shown unparalleled durable responses in hematological tumors.Immunosuppressive cells and molecules in the tumor microenvironment(TME)limit the infiltration and cytotoxicity of CAR-T cells at the tumor site.Therefore,the significant efficacy of CAR-T cell therapy in hematological tumors is not present in solid tumors.Here we take an overview of how to break through the TME restriction,improve the homing ability and cytotoxicity of CAR-T cells,and thus improve its efficacy in solid tumors.
作者
关丽萍
蒋敬庭
吴昌平
GUAN Liping;JIANG Jingting;WU Changping(Department of Tumor Biological Treatment,the Third People s Hospital Affiliated to Soochow University,Institute of Cell Therapy,Soochow University,Changzhou 213003,China)
出处
《临床肿瘤学杂志》
CAS
北大核心
2020年第3期264-267,共4页
Chinese Clinical Oncology
基金
国家重点研发资助项目(2018YFC1313400)
国家科技支撑计划资助项目(2015BAI12B12)
国家自然科学基金海外及港澳学者合作研究资助项目(31729001)
国家自然科学基金资助项目(31570877,31570908)
江苏省重点研发计划专项资助项目(BE2018645)。
关键词
实体肿瘤
嵌合型抗原受体
肿瘤微环境
Solid tumors
Chimeric antigen receptor(CAR)
Tumor microenvironment(TME)
